iBio (NASDAQ:IBIO – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.
Earnings & Valuation
This table compares iBio and Pluri”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iBio | $100,000.00 | 758.86 | -$33.04 million | ($0.34) | -3.47 |
| Pluri | $1.02 million | 13.80 | -$23.82 million | ($2.45) | -0.47 |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for iBio and Pluri, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iBio | 1 | 0 | 4 | 3 | 3.12 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
iBio presently has a consensus price target of $5.00, indicating a potential upside of 323.73%. Given iBio’s stronger consensus rating and higher probable upside, equities analysts clearly believe iBio is more favorable than Pluri.
Risk & Volatility
iBio has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
Insider & Institutional Ownership
7.9% of iBio shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 1.5% of iBio shares are held by company insiders. Comparatively, 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares iBio and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iBio | N/A | -40.66% | -35.78% |
| Pluri | -2,344.59% | N/A | -82.71% |
Summary
iBio beats Pluri on 9 of the 15 factors compared between the two stocks.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
